CA-AGENDIA
Agendia, Inc. , a world leader in precision oncology for breast cancer, today shared data demonstrating the ability of MammaPrint® and BluePrint® to predict patient outcomes following neoadjuvant chemotherapy (NAC) at the 2021 San Antonio Breast Cancer Symposium (SABCS 2021).
The poster, titled MammaPrint and BluePrint are prognostic of outcome following neoadjuvant chemotherapy , presents findings that indicate MammaPrint and BluePrint accurately correlated with chemosensitivity and outcomes in NAC-treated patients. The research was conducted in collaboration with Cedars-Sinai Medical Center.
Notably, approximately 1 in 4 tumors which were MammaPrint High Risk (Luminal B) prior to NAC became MammaPrint Low Risk (Luminal A) when the post-treatment tissue was analyzed. Patients with reclassified MammaPrint Low Risk tumors had improved five-year outcomes compared to patients that remained High Risk after treatment. These data signal a role for serial genomic testing to determine proper classification of breast cancer tumors following NAC treatment in order to appropriately manage a woman’s future treatment plan and prognosis.
“By analyzing MammaPrint and BluePrint on pre- and post-NAC tissue samples for those with residual disease, we unlock new insights about their clinical utility and potential impact on treatment decisions given the biological changes that may occur following initial intervention,” said Alice P. Chung, MD, Division of Surgical Oncology, Department of Surgery, Cedars-Sinai Medical Center. “The importance of accurate genomic classification of a tumor is crucial, especially in the context of these findings where 1 in 4 High Risk tumors became Low Risk – insights which can significantly affect our treatment planning discussions with patients.”
The analysis presented at SABCS 2021 features data from 128 women (median age 50) with stage I-III early breast cancer (EBC), of any clinical subtype, diagnosed from 2007-2016 who received NAC at Cedars-Sinai Medical Center. Among 111 pre-treated tumors, MammaPrint High Risk tumors had a significantly higher pathological complete response (pCR) rate than Low Risk tumors. Amongst tumors that had discordant MammaPrint results between pre- and post-treatment samples, the only change observed was from High Risk to Low Risk. BluePrint results were very consistent between pre- and post-NAC samples (92% concordance) with reclassification only occurring in the HER2-Type cohort, consistent with the known heterogeneity in clinically HER2-positive tumors.
“Neoadjuvant chemotherapy is the standard of care for the initial treatment of certain types of breast cancer, and for many women, the clinical response to therapy is thought to carry prognostic implications. This study illustrates the additional information provided by our genomic assays regarding response to therapy and prognosis,” said William Audeh, MD, Chief Medical Officer at Agendia and a study author. “While changes in the MammaPrint Risk index with treatment are clearly associated with outcome, it is also important to note the consistency of BluePrint results pre- and post- treatment with neoadjuvant chemotherapy. These data further demonstrate the prognostic accuracy of the assays and confirm the importance of genomic information in our quest to identify better biomarkers in patients treated with neoadjuvant chemotherapy.”
Future studies will study the effect of NAC on the breast cancer transcriptome and its association with clinical outcomes.
About Agendia
Agendia is a mission-driven company focused on enabling optimized treatment planning by providing physicians with next-generation diagnostic and information solutions that can be used to help improve outcomes and quality of life for breast cancer patients worldwide. The company currently offers two commercially-available genomic profiling tests that help surgeons, oncologists and pathologists to personalize treatment for women at critical intervention points throughout their patient journey.
MammaPrint® is a 70-gene prognostic test that, along with other clinicopathologic factors, determines a specific patient’s breast cancer recurrence risk. BluePrint® is an 80-gene molecular subtyping test that identifies the underlying biology of an individual breast cancer to provide information about its behavior, long-term prognosis and potential response to systemic therapy. Together, MammaPrint® and BluePrint® provide a holistic view of an individual patient’s breast cancer, enabling physicians to objectively select the best treatment plan.
For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211209006022/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Megaport to Acquire Latitude.sh, Creating an Industry-leading Compute and Network-as-a-Service Platform to Power High-performance Applications and AI Workloads Globally10.11.2025 23:17:00 CET | Press release
Megaport Limited (ASX: MP1), the world’s leading Network-as-a-Service (NaaS) provider, today announced it has entered into an agreement to acquire Latitude.sh, a leading global Compute-as-a-Service company delivering high-performance CPU and GPU infrastructure on demand. Following completion of the acquisition, the combined capabilities will create a global platform that unites Megaport’s private, high-speed connectivity fabric with Latitude.sh’s compute infrastructure, enabling enterprises to rapidly deploy and connect critical workloads across more than 1,000 data centres in 26 countries. “Megaport has long been trusted by the world’s largest enterprises to move workloads seamlessly between data centers and the cloud,” said Michael Reid, CEO of Megaport. “By bringing Latitude.sh into the fold, we’re extending that promise beyond the network, and into high-performance, optimized compute, complementing cloud providers. Together, we will not only serve the massive traditional compute ma
Svante and Södra Launch EU-Based Carbon Capture Pilot to Advance Biogenic CO₂ Utilization10.11.2025 22:49:00 CET | Press release
Svante Technologies Inc. (“Svante”), a global leader in solid sorbent-based carbon capture and removal solutions, is proud to share that Södra, Sweden’s largest forest-owner association, has announced it will test Svante’s carbon capture technology at the Värö industrial site in early 2026 and evaluate opportunities for large-scale capture in the future. This pilot project marks Svante’s first deployment in the EU forestry sector and represents a significant step toward scaling biogenic carbon capture in pulp and paper production. The pilot will evaluate the performance of Svante’s proprietary solid sorbent filters in capturing biogenic CO₂ emissions from Södra’s pulp operations, with the goal of enabling new circular value chains and supporting Sweden’s climate targets. A Strategic Step Toward Circular Bioeconomy Södra’s pulp production generates biogenic CO₂, which is a renewable carbon source with potential applications across food, water purification, chemical manufacturing, and e-
GGPoker Launches Online Poker Millionaires - A New Docuseries Showcasing The High-Stakes Online Poker World Of GGPoker10.11.2025 21:02:00 CET | Press release
Online Poker Millionaires Episode 1 to premiere on GGPoker’s YouTube channel this Wednesday, November 12 GGPoker, the World’s Biggest Poker Room, is excited to launch Online Poker Millionaires, a new docuseries that takes viewers inside the world of high-stakes online poker. The series trailer will go live on GGPoker’s official YouTube channel on Monday, November 10, with Episode 1 featuring Alex Theologis made available on Wednesday, November 12. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251110029569/en/ GGPoker Online Poker Millionaires Documentary Series Series Description Online Poker Millionaires is produced in association with POKERfilms and reveals how the game’s most dedicated players turn a laptop, ambition, and discipline into real financial success. Online poker isn’t just a game - for some, it can be a path to financial success, where real money and real careers are built at GGPoker. Each episode follows a d
TOURISE and Oxford Economics Release White Paper Charting Tourism’s Path to Resilience and Stability Amid Global Volatility10.11.2025 17:10:00 CET | Press release
International travel projected to exceed 2 billion arrivals by 2030, despite global economic and geopolitical uncertaintyStrategic investment in infrastructure, policy, and accessibility key to unlocking continued growth TOURISE, in collaboration with Oxford Economics, has released a new white paper titled “Growth Amid Uncertainty: Opportunities and Risks on the Road to 2 Billion Global Travellers,” unveiled during the inaugural TOURISE Summit. The publication presents key opportunities and risks that the industry will face in coming years as well as a framework to guide policymakers, destination leaders, and industry stakeholders in strengthening the tourism sector’s capacity to withstand global disruptions and foster long-term sustainability and resilience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251110254503/en/ TOURISE and Oxford Economics Release White Paper Charting Tourism’s Path to Resilience and Stability Ami
Altman Solon Selects Mindbreeze to Power Knowledge Management and Collaboration Across the Organization10.11.2025 16:01:00 CET | Press release
Mindbreeze, a leading global provider of AI-based knowledge management solutions, today announced that Altman Solon, the world’s largest strategy consulting firm focused exclusively on telecommunications, media, and technology (TMT), has purchased Mindbreeze InSpire. The collaboration began in July 2025 with a trial of the Mindbreeze Insight Workplace, designed to unify Altman Solon’s SharePoint and web-based data sources into a single point of entry for organizational knowledge. Before partnering with Mindbreeze, Altman Solon sought to enhance how its global teams accessed and shared knowledge across systems, a challenge common among consulting firms with vast, fast-growing data ecosystems. The company had built a strong foundation in SharePoint for managing structured project data, but its native search capabilities limited visibility across platforms. Project information was distributed across several secure repositories, making it difficult to form a single, holistic view of our co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom